Purple Biotech Ltd (TLV: PPBT)
Israel
· Delayed Price · Currency is ILS · Price in ILA7.90
-0.30 (-3.66%)
Oct 15, 2024, 5:24 PM IDT
Purple Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cost of Revenue | 0.2 | 0.2 | 0.12 | 0.06 | 0.06 | 0.08 | Upgrade
|
| Gross Profit | -0.2 | -0.2 | -0.12 | -0.06 | -0.06 | -0.08 | Upgrade
|
| Selling, General & Admin | 3.83 | 5.04 | 6.03 | 6.04 | 5.9 | 3.96 | Upgrade
|
| Research & Development | 15.65 | 17.03 | 16.32 | 11.83 | 7.24 | 2.28 | Upgrade
|
| Operating Expenses | 19.47 | 22.08 | 22.35 | 17.87 | 13.14 | 6.24 | Upgrade
|
| Operating Income | -19.67 | -22.27 | -22.47 | -17.92 | -13.2 | -6.32 | Upgrade
|
| Interest & Investment Income | 0.52 | 0.47 | 0.53 | 0.32 | 0.25 | 0.15 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.06 | -0.13 | -0.01 | -0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 3.25 | 1.83 | 0.25 | -0.08 | -15.71 | 1.43 | Upgrade
|
| EBT Excluding Unusual Items | -15.91 | -19.98 | -21.63 | -17.81 | -28.66 | -4.84 | Upgrade
|
| Legal Settlements | - | - | -0.14 | -0.01 | -0.04 | -0.36 | Upgrade
|
| Pretax Income | -16.11 | -19.98 | -21.76 | -17.83 | -28.7 | -5.19 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 0.22 | Upgrade
|
| Earnings From Continuing Operations | -16.11 | -19.98 | -21.76 | -17.83 | -28.7 | -5.41 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | -0.64 | 0.63 | -0.49 | Upgrade
|
| Net Income to Company | -16.11 | -19.98 | -21.76 | -18.47 | -28.07 | -5.89 | Upgrade
|
| Minority Interest in Earnings | 0.08 | 0.1 | 0.09 | 0.08 | 0.08 | 0.04 | Upgrade
|
| Net Income | -16.03 | -19.88 | -21.67 | -18.38 | -28 | -5.85 | Upgrade
|
| Net Income to Common | -16.03 | -19.88 | -21.67 | -18.38 | -28 | -5.85 | Upgrade
|
| Shares Outstanding (Basic) | 253 | 221 | 181 | 176 | 115 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 253 | 221 | 181 | 176 | 115 | 19 | Upgrade
|
| Shares Change (YoY) | 30.82% | 22.41% | 2.92% | 52.76% | 493.78% | 36.34% | Upgrade
|
| EPS (Basic) | -0.06 | -0.09 | -0.12 | -0.10 | -0.24 | -0.30 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.09 | -0.12 | -0.10 | -0.24 | -0.30 | Upgrade
|
| Free Cash Flow | -17.7 | -19.93 | -16.76 | -15.37 | -12.25 | -5.59 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.09 | -0.09 | -0.09 | -0.11 | -0.29 | Upgrade
|
| EBITDA | -19.62 | -22.23 | -22.42 | -17.69 | -12.96 | -6.14 | Upgrade
|
| D&A For EBITDA | 0.04 | 0.05 | 0.05 | 0.23 | 0.24 | 0.18 | Upgrade
|
| EBIT | -19.67 | -22.27 | -22.47 | -17.92 | -13.2 | -6.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.